|
1
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Burtness B, Harrington KJ, Greil R,
Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane
P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic
squamous cell carcinoma of the head and neck (KEYNOTE-048): A
randomised, open-label, phase 3 study. Lancet. 394:1915–1928.
2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pitt JM, Marabelle A, Eggermont A, Soria
JC, Kroemer G and Zitvogel L: Targeting the tumor microenvironment:
Removing obstruction to anticancer immune responses and
immunotherapy. Ann Oncol. 27:1482–1492. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Murciano-Goroff YR, Warner AB and Wolchok
JD: The future of cancer immunotherapy: Microenvironment-targeting
combinations. Cell Res. 30:507–519. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Alečković M, McAllister SS and Polyak K:
Metastasis as a systemic disease: Molecular insights and clinical
implications. Biochim Biophys Acta Rev Cancer. 1872:89–102.
2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Diakos CI, Charles KA, McMillan DC and
Clarke SJ: Cancer-related inflammation and treatment effectiveness.
Lancet Oncol. 15:e493–e503. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Janssen LME, Ramsay EE, Logsdon CD and
Overwijk WW: The immune system in cancer metastasis: Friend or foe?
J Immunother Cancer. 5(79)2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dolan RD, Laird BJA, Horgan PG and
McMillan DC: The prognostic value of the systemic inflammatory
response in randomised clinical trials in cancer: A systematic
review. Crit Rev Oncol Hematol. 132:130–137. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gutkin DW and Shurin MR: Clinical
evaluation of systemic and local immune responses in cancer: Time
for integration. Cancer Immunol Immunother. 63:45–57.
2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mego M, Gao H, Cohen EN, Anfossi S,
Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward
WA, et al: Circulating tumor cells (CTC) are associated with
defects in adaptive immunity in patients with inflammatory breast
cancer. J Cancer. 7:1095–1104. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Ye L, Zhang F, Li H, Yang L, Lv T, Gu W
and Song Y: Circulating tumor cells were associated with the number
of T lymphocyte subsets and NK cells in peripheral blood in
advanced non-small-cell lung cancer. Dis Markers.
2017(5727815)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tada H, Takahashi H, Kuwabara-Yokobori Y,
Shino M and Chikamatsu K: Molecular profiling of circulating tumor
cells predicts clinical outcome in head and neck squamous cell
carcinoma. Oral Oncol. 102(104558)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W,
Zhang X, Wang WM, Qiu SJ, Zhou J and Fan J: Systemic
immune-inflammation index predicts prognosis of patients after
curative resection for hepatocellular carcinoma. Clin Cancer Res.
20:6212–6222. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Onodera T, Goseki N and Kosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.PubMed/NCBI(In Japanese).
|
|
15
|
Ranzani OT, Zampieri FG, Forte DN, Azevedo
LC and Park M: C-reactive protein/albumin ratio predicts 90-day
mortality of septic patients. PLoS One. 8(e59321)2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Jiang W, Chen Y, Huang J, Xi D, Chen J,
Shao Y, Xu G, Ying W, Wei J, Chen J, et al: Systemic
immune-inflammation index predicts the clinical outcome in patients
with nasopharyngeal carcinoma: A propensity score-matched analysis.
Oncotarget. 8:66075–66086. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Diao P, Wu Y, Li J, Zhang W, Huang R, Zhou
C, Wang Y and Cheng J: Preoperative systemic immune-inflammation
index predicts prognosis of patients with oral squamous cell
carcinoma after curative resection. J Transl Med.
16(365)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Szilasi Z, Jósa V, Zrubka Z, Mezei T, Vass
T, Merkel K, Helfferich F and Baranyai Z: Neutrophil-to-lymphocyte
and platelet-to-lymphocyte ratios as prognostic markers of survival
in patients with head and neck tumours-results of a retrospective
multicentric study. Int J Environ Res Public Health.
17(1742)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Takahashi H, Sakakura K, Tada H, Kaira K,
Oyama T and Chikamatsu K: Prognostic significance and population
dynamics of peripheral monocytes in patients with oropharyngeal
squamous cell carcinoma. Head Neck. 41:1880–1888. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899.
2010.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng
C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, et al: Cytokine
profile and prognostic significance of high neutrophil-lymphocyte
ratio in colorectal cancer. Br J Cancer. 112:1088–1097.
2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yersal Ö, Çetinkünar S, Aktimur R, Aziret
M, Özdaş S, Erdem H and Yildirim K: Neutrophil/lymphocyte and
platelet/lymphocyte ratios are not different among breast cancer
subtypes. Asian Pac J Cancer Prev. 18:2227–2231. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cao Z, Ji J, Zhang C, Wang F, Xu H, Yu Y
and Sun Y: The preoperative neutrophil-to-lymphocyte ratio is not a
marker of prostate cancer characteristics but is an independent
predictor of biochemical recurrence in patients receiving radical
prostatectomy. Cancer Med. 8:1004–1012. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Samuels Y and Ericson K: Oncogenic PI3K
and its role in cancer. Curr Opin Oncol. 18:77–82. 2006.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rogers SJ, Box C, Harrington KJ, Nutting
C, Rhys-Evans P and Eccles SA: The phosphoinositide 3-kinase
signalling pathway as a therapeutic target in squamous cell
carcinoma of the head and neck. Expert Opin Ther Targets.
9:769–790. 2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen X, Cao Y, Sedhom W, Lu L, Liu Y, Wang
H, Oka M, Bornstein S, Said S, Song J and Lu SL: Distinct roles of
PIK3CA in the enrichment and maintenance of cancer stem cells in
head and neck squamous cell carcinoma. Mol Oncol. 14:139–158.
2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
García-Escudero R, Segrelles C, Dueñas M,
Pombo M, Ballestín C, Alonso-Riaño M, Nenclares P,
Álvarez-Rodríguez R, Sánchez-Aniceto G, Ruíz-Alonso A, et al:
Overexpression of PIK3CA in head and neck squamous cell carcinoma
is associated with poor outcome and activation of the YAP pathway.
Oral Oncol. 79:55–63. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Sivaram N, McLaughlin PA, Han HV, Petrenko
O, Jiang YP, Ballou LM, Pham K, Liu C, van der Velden AW and Lin
RZ: Tumor-intrinsic PIK3CA represses tumor immunogenecity in a
model of pancreatic cancer. J Clin Invest. 129:3264–3276.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Willingham SB, Volkmer JP, Gentles AJ,
Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin
R, Cohen JD, et al: The CD47-signal regulatory protein alpha
(SIRPa) interaction is a therapeutic target for human solid tumors.
Proc Natl Acad Sci USA. 109:6662–6667. 2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Baccelli I, Stenzinger A, Vogel V,
Pfitzner BM, Klein C, Wallwiener M, Scharpff M, Saini M,
Holland-Letz T, Sinn HP, et al: Co-expression of MET and CD47 is a
novel prognosticator for survival of luminal breast cancer
patients. Oncotarget. 5:8147–8160. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wang H, Tan M, Zhang S, Li X, Gao J, Zhang
D, Hao Y, Gao S, Liu J and Lin B: Expression and significance of
CD44, CD47 and c-met in ovarian clear cell carcinoma. Int J Mol
Sci. 16:3391–3404. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Sakakura K, Takahashi H, Kaira K, Toyoda
M, Murata T, Ohnishi H, Oyama T and Chikamatsu K: Relationship
between tumor-associated macrophage subsets and CD47 expression in
squamous cell carcinoma of the head and neck in the tumor
microenvironment. Lab Invest. 96:994–1003. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Matozaki T, Murata Y, Okazawa H and
Ohnishi H: Functions and molecular mechanisms of the CD47-SIRPalpha
signalling pathway. Trends Cell Biol. 19:72–80. 2009.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Adams S, van der Laan LJ, Vernon-Wilson E,
Renardel de Lavalette C, Döpp EA, Dijkstra CD, Simmons DL and van
den Berg TK: Signal-regulatory protein is selectively expressed by
myeloid and neuronal cells. J Immunol. 161:1853–1859.
1998.PubMed/NCBI
|
|
37
|
Kharitonenkov A, Chen Z, Sures I, Wang H,
Schilling J and Ullrich A: A family of proteins that inhibit
signalling through tyrosine kinase receptors. Nature. 386:181–186.
1997.PubMed/NCBI View
Article : Google Scholar
|
|
38
|
Rozali EN, Hato SV, Robinson BW, Lake RA
and Lesterhuis WJ: Programmed death ligand 2 in cancer-induced
immune suppression. Clin Dev Immunol. 2012(656340)2012.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 expression. Cell Rep. 19:1189–1201. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yoshida T, Ichikawa J, Giuroiu I, Laino
AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Stephen Hodi F and
Weber J: C reactive protein impairs adaptive immunity in immune
cells of patients with melanoma. J Immunother Cancer.
8(e000234)2020.PubMed/NCBI View Article : Google Scholar
|
